Serological activity in clinically quiescent SLE: To treat or not to treat in the biologic era?

Abstract

Keywords

Lupus diseases activity anti-DNA complement SLE

Get full access to this article

View all access options for this article.

References

Yanagimoto

Minowa

Yoshida

, et al. Efficacy of adding belimumab to hydroxychloroquine for patients with serologically active clinically quiescent in systemic lupus erythematosus: a retrospective study. Lupus 2025. [In Press]. DOI: 10.1177/09612033251401641.

Ayano

Hirata

Tokunaga

, et al. No clear influence of treatment escalation on flare prevention in serologically active clinically quiescent patients with systemic lupus erythematosus: a retrospective cohort study. Rheumatol Int 2024; 44(11): 2411–2419.

Ding

Zhou

Zhan

, et al. Phenotypic subgroup in serologically active clinically quiescent systemic lupus erythematosus: a cluster analysis based on CSTAR cohort. Méd Sur 2024; 5(10): 1266–1274.e3.

Chen

Deng

, et al. Short-term incremental prednisone therapy in patients with serologically active clinically quiescent lupus nephritis: a retrospective observational study. Eur J Med Res 2024; 29(1): 555.

Katsumata

Inoue

Harigai

, et al. Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study. Ann Rheum Dis 2024; 83(8): 998–1005.

Niyompanichakarn

Chaiamnuay

Narongroeknawin

, et al. The effect of gradual withdrawal versus maintenance of low-dose glucocorticoid in clinically quiescent systemic lupus erythematosus, a pilot double-blind randomised controlled trial. Muscoskel Care 2025; 23(2): e70083.

Huang

Zhang

, et al. Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study. Arthritis Res Ther 2021; 23(1): 275.